Aerogen and CanSinoBio announced today that they entered a partnership to deliver the latter’s COVID-19 vaccine with Aerogen’s technology. Galway, Ireland-based Aerogen’s proprietary vibrating mesh aerosol drug delivery technology will be used to deliver CanSinoBio’s recombinant novel coronavirus vaccine — Convidecia — under the development and commercial supply partnership. Commercial terms for the partnership were not disclosed. Get […]
Aerogen and Lyomark Pharma said today that they inked a deal to develop an inhaled surfactant treatment for respiratory distress syndrome in pre-term infants. The pact calls for the duo to combine a compound called AP-002, a nasally inhaled surfactant based on a combination of Lyomark’s Alveofact bovine lung surfactant and Aerogen’s PDAP nasal delivery technology. Aerogen […]
Aerogen today touted results from a study showing a 32% reduction in hospital admissions when patients were treated using its Solo vibrating mesh aerosol drug delivery system, compared to a small-volume nebulizer. The Chicago-based company’s vibrating mesh is used to treat respiratory disorders such as COPD, asthma, or influenza, all of which are exacerbated in the […]
MASSDEVICE ON CALL — There were gains and losses reported this week for the global medical device workforce, with unrelated announcements from Arizona and Ireland.
Flagstaff, Ariz.-based Machine Solutions said that it cut about 20 workers, citing a "challenging business environment" and sluggish sales for its catheter business.
Aerogen Ltd. and Dance Pharmaceuticals signed a deal to develop an insulin inhalation device for diabetics.
The companies’ planned product would allow millions of diabetics to avoid sticking themselves with needles several times a day to treat the disease with insulin injections.